|| ARIAD Pharmaceuticals
|| Lung Cancer
|| ALK-positive NSCLC
| Mode of Action
|| ALK inhibitor (targeted therapy)
| Approval Status
|| FDA approved (USA)
|| 30 mg
Who is brigatinib for?
Alunbrig (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who are intolerant to crizotinib, or who experienced the progression of their disease during or after the treatment with crizotinib . Crizotinib is a drug for ALK-positive NSCLC widely approved (e.g. in USA by FDA  and in Europe by EMA ).
Complete information about Alunbrig (brigatinib) dosage and administration can be found here: .The standard dosage is:
Administer brigatinib until disease progression or unacceptable toxicity. If the dose is not tolerated, the recommended dose reduction levels can be found in the prescribing information: .Consult your treating doctor for personalised dosing.
- 90 mg orally once daily for the first 7 days;
- if tolerated, increase to 180 mg orally once daily.
What is brigatinib and how does it work?
Alunbrig (brigatinib) is a kinase inhibitor used to treat adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who are intolerant to crizotinib, or who experienced the progression of their disease during or after the treatment with crizotinib .The ALK (anaplastic lymphoma kinase) gene plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system . Mutations of the ALK gene can occur in several different types of cells, including lung cells, and can result in the development of a tumour . ALK gene mutations occur in 3 to 7 % of patients with NSCLC .Patients who have advanced ALK-positive NSCLC are generally highly responsive to ALK inhibitor crizotinib . However, almost all patients treated with crizotinib experience progression of their disease, which results in the development of secondary ALK mutations that are resistant to this therapeutics. Approximately 40 % of the ALK-positive NSCLC patients develop metastases in their central nervous system (brain and spinal cord), as an initial site of progression .Similarly to crizotinib and alectinib, brigatinib is an ALK-inhibitor, which acts by inhibiting the activity of the ALK protein, and may prevent ALK-positive NSCLC-cells from growing and spreading . Alunbrig (brigatinib) offers an additional option to patients who developed resistance to crizotinib.
What is brigatinib's approval status?
Alunbrig (brigatinib) was approved by:
for patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib .The approval was based on a study (ALTA) involving 222 patients with locally advanced or metastatic ALK+ NSCLC who had progressed on crizotinib. The overall response rate was 53 % [95% CI: 43, 62] with 4.5 % complete response rate (as assessed by an Independent Review Committee (IRC)), and the median duration of response was 13.8 months [95 % CI: 5.6, 13.8] as assessed by an IRC. Additionally, 67 % [95 % CI: 41, 87] of patients with measurable brain metastases achieved a confirmed intracranial overall response which lasted about 6 months .
- FDA (US) on April 28, 2017
The most common adverse reactions were nausea, diarrhea, fatigue, cough, and headache 
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.